The synergistic effects of TCP (a LSD1 inhibitor) and GSK-J1 (a JMJD3 inhibitor) against HNSCC were determined in vitro and in preclinical animal models. The gene discussed is KDM6B; the disease is head and neck squamous cell carcinoma.